Pterygopalatine fossa, a hive for fungus in rhino orbital mucormycosis: a case series


  • Prasanna Darla Department of Otorhinolaryngology, Alluri Sitarama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India
  • Jaya Sandeep Siripalli Department of Otorhinolaryngology, Alluri Sitarama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India
  • Mohanty Deeganta Department of Otorhinolaryngology, Alluri Sitarama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India



PPF, Rhino orbital mucormycosis, COVID-19, Liposomal amphotericin-B, Modified Denker’s approach, Maxillectomy


The study aims to evaluate the involvement of pterygopalatine fossa (PPF) in rhino orbital mucormycosis and to study various outcomes that occurred as a result of the interventions. We conducted a retrospective; observational study performed using KOH mounts, histopathology, computed tomography paranasal sinuses (CT PNS) scans from June 1 to July 31 in 2021 at Alluri Sitarama Raju academy of medical sciences and hospital, Eluru. A total of 39 cases were admitted during that period. Patients were administered with liposomal amphotericin-B injection, and surgical debridement of local tissues was performed via endoscopic sinus surgery (ESS), modified endoscopic Denker's approach, orbitotomy and maxillectomy. Out of 39 patients, 29 (74.3%) patients had the involvement of PPF using CT PNS. Most of the patients were male (71.8%). The 10% potassium hydroxide (KOH) mounts were found positive in 71.8%. The 94.8% of patients had a history of COVID-19 infection. ESS via modified Denker’s approach was performed in 53.8%. Our findings show that PPF involvement is the main conduit for the aggressive spread of the rhino orbital mucormycosis disease. Therefore, further treatment with medical and surgical techniques could effectively halt the fatal outcomes of the disease at the earliest stages.



Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi. 2020;6(4):265.

Honavar SG. Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol. 2021;69(6):1361-5.

Revannavar SM, Supriya PS, Samaga L, Vineeth VK. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep CP. 2021;14(4):e241663.

Cappello ZJ, Potts KL. Anatomy, Pterygopalatine Fossa. Treasure Island (FL): Stat Pearls Publishing. 2022.

Ilahi S. Physiology, pineal gland. Stat Pearls Available at: Accessed on 29 April 2021.

Paltauf A. Mycosis Mucorina. Virchows Arch Pathol Anat Physiol Klin Med. 1885;102:543-64.

Naussbaum ES, Holl WA. Rhinocerebral mucormycosis: changing patterns of disease. Surg Neurol. 1994;41:152-6

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(1):S16-22.

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301.

Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. 1982;31(12):1109-14.

Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS pathog. 2017;13(8):e1006408.

Liu M, Lin L, Gebremariam T, Luo G, Skory CD, French SW et al. Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine. PLoS Pathog. 2015;11(5):e1004842.

Liu M, Spellberg B, Phan QT, Fu Y, Lee AS, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120(6):1914-24.

Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, Edwards JE Jr et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest. 2016;126(6):2280-94.

Binder U, Maurer E, Lass-Flörl C. Mucormycosis-from the pathogens to the disease. Clin Microbiol Infect. 2014;20(6):60-6.

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301. 2021;398.

Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: A tale of two pathogens Indian J Ophthalmol. 2021;69:244-52.

Sreshta K, Dave TV, Varma DR, Nair AG, Bothra N, Naik MN et al. Magnetic resonance imaging in rhino-orbital-cerebral mucormycosis. Indian J Ophthalmol. 2021;69(7):1915-27.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in co-operation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405-21.

Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Chen SCA, Kong DCM. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. Int J Antimicrob Agents. 2019;53:589-97.

Brunet K, Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. J Mycol Med. 2020;30:101007.

Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D’Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003;51:231-6.

Vaid N, Mishra P, Gokhale N, Vaid S, Vaze V, Kothadiya A et al. A proposed grading system and experience of COVID-19 associated rhino orbito cerebral mucormycosis from an Indian Tertiary Care Center. Indian J Otolaryngol Head Neck Surg. 2021;1-8.






Case Series